---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-012244"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:14:51.171167+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned

## Summary
- HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.
- OraTech to launch Phase 3 trial of oral insulin (ORMD-0801) in US this quarter with revised protocol.
- HTIT provides supply agreement for oral insulin capsules; OraTech gets global marketing rights to Oramed's POD technology.
- OraTech also receives license for oral semaglutide (HT01B) from HTIT for markets outside greater China.
- Initial closing deadline extended to April 30, 2025; second closing by May 31, 2025 if Nasdaq listing delayed.

## SEC filing metadata
- accession: 0001213900-25-012244
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025012244/0001213900-25-012244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025012244/ea0229914-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-012244
- JSON: https://secwatch.observer/filing/0001213900-25-012244.json
- Plain text: https://secwatch.observer/filing/0001213900-25-012244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.